Key result
Sacubitril/valsartan significantly increased left ventricular ejection fraction from 38.09% at baseline to 52% at 6 months (p<0.001) in pediatric patients with advanced heart failure.
Why the study?
Pediatric heart failure is a significant cause of illness and death, prompting an assessment of sacubitril/valsartan's effectiveness and proper dosage in pediatric patients.
Does low-dose sacubitril/valsartan improve echocardiographic parameters and NT-proBNP in pediatric patients with advanced heart failure unresponsive to traditional therapy?
Cohort (n=23)
Does low-dose sacubitril/valsartan improve echocardiographic parameters and NT-proBNP in pediatric patients with advanced heart failure unresponsive to traditional therapy?
Low-dose sacubitril/valsartan significantly improves left ventricular ejection fraction, reduces heart size, and lowers NT-proBNP in pediatric patients with advanced heart failure.
May support low-dose sacubitril/valsartan in pediatric advanced HF; hypothesis-generating pending randomized trials.
• Assess sacubitril/valsartan's effectiveness and find the proper dosage for pediatric heart failure patients. • Patients with no improvement in traditional medicine were studied. • Echocardiography, NT-proBNP, and the concentration of valsartan, sacubitril, sacubitrilat were measured. • Low dose sacubitril/valsartan is effective in children with heart failure. Aims: Pediatric heart failure is a significant cause of illness and death in children. We aimed to assess sacubitril/valsartan's effectiveness and find the proper dosage for pediatric patients. Methods: Patients unresponsive to traditional medicines for at least 12 months prescribed sacubitril/valsartan from January 2020 to March 2023 were reviewed. The initial dose was 0.2 mg/kg bid, gradually increasing in 0.1 mg/kg increments. The target dose was determined based on blood pressure fluctuations at 70/50 mmHg. Clinical efficacy and quantity-effect relationship were evaluated using echocardiography, NT-proBNP, and the concentration of valsartan, sacubitril, sacubitrilat. Results: A total of 23 pediatric patients with dilated cardiomyopathy and advanced heart failure were enrolled. Mean sacubitril/valsartan dose was 1.84 mg/kg/day. After 6 months, LVEF increased significantly (38.09% to 45% at 3 months, 52% at 6 months; p < 0.001). LV size reduced to 4.4 cm (IQR, 4.1-5.2) and 4.5 cm (IQR, 4-5.1) at 3 and 6 months, respectively, from 4.6 cm (IQR, 4.2-5.6) at baseline (both P < 0.05). NT-proBNP levels reduced by 5.7 at 3 months (p < 0.05) and 5.38 at 6 months (p < 0.001). Sacubitrilat is the active form of Sacubitril. The highest concentration of sacubitrilat was observed at approximately 1.6 mg/kg. The maintenance dose correlated positively with time (p < 0.001) and valsartan/sacubitril concentration (p < 0.05). Conclusion: Low dose sacubitril/valsartan is effective in children with heart failure, with dosage adjustments to avoid hypotension. Adjusted dosing can increase EF and reduce heart size, offering new possibilities for pediatric heart failure treatment.
No takes yet. Share an insight, caveat, or question.
Zha et al. (2024) conducted a cohort in pediatric heart failure and dilated cardiomyopathy (n=23). sacubitril/valsartan was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Sacubitril/valsartan significantly increased left ventricular ejection fraction from 38.09% at baseline to 52% at 6 months (p<0.001) in pediatric patients with advanced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: